Synthesis and evaluation of nitroheterocyclic phosphoramidates as hypoxia-selective alkylating agents

Journal of Medicinal Chemistry

Volumn 43, Issue 11, 2000, Pages 2258-2265

  Borch, Richard F ^a,b   Liu, Jiwen ^a   Schmidt, James P ^a   Marakovits, Joseph T ^a   Joswig, Carolyn ^a   Gipp, Jerry J ^c   Mulcahy, R Timothy ^c  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b PURDUE UNIVERSITY   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HETEROCYCLIC COMPOUND; NITRO DERIVATIVE; PHOSPHORAMIDE MUSTARD; PHOSPHORAMIDIC ACID DERIVATIVE;

AEROBIC METABOLISM; ALKYLATION; ARTICLE; CELL HYPOXIA; CHEMICAL ANALYSIS; CLONOGENIC ASSAY; CYTOTOXICITY; HUMAN; HUMAN CELL; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL HYPOXIA; DRUG SCREENING ASSAYS, ANTITUMOR; HT29 CELLS; HUMANS; MELANOMA, EXPERIMENTAL; MICE; ORGANOPHOSPHORUS COMPOUNDS; OXYGEN; TUMOR CELLS, CULTURED;

EID: 0034212605     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0001020     Document Type: Article

References (25)

1. (a) Coleman, C. N. Hypoxia in tumors: A paradigm for the approach to biochemical and physiologic heterogeneity. J. Natl. Cancer Inst. 1988, 80, 310-317.
2. (b) Vaupel, P.; Kallinowski, F.; Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989, 49, 6449-6465.
3. (c) Moulder, J. E.; Rockwell, S. Tumor hypoxia: Its impact on cancer therapy. Cancer Metastasis Rev. 1982, 5, 313-341.
4. (a) Rockwell, S. Use of hypoxia-directed drugs in the therapy of solid tumors. Semin. Oncol. 1992, 19, 29-40.
5. (b) Denny, W. A.; Wilson, W. R.; Hay, M. P. Recent developments in the design of bioreductive drugs. Br. J. Cancer - Suppl. 1996, 27, S32-S38.
6. (c) Jaffar, M.; Naylor, M. A.; Robertson, N.; Stratford, I. J. Targeting hypoxia with a new generation of indolequinones. Anti-Cancer Drug Des. 1998, 13, 593-609.
7. (d) Rockwell, S.; Sartorelli, A. C.; Tomasz, M.; Kennedy, K. A. Cellular pharmacology of quinone bioreductive alkylating agents. Cancer Metastasis Rev. 1993, 12, 165-176.
8. (e) Siim, B. G.; Atwell, G. J.; Anderson, R. F.; Wardman, P.; Pullen, S. M.; Wilson, W. R.; Denny, W. A. Hypoxia-selective antitumor agents. 15. Modification of rate of nitroreduction and extent of lysosomal uptake by polysubstitution of 4-(alkylamino)-5-nitroquinoline bioreductive drugs. J. Med. Chem. 1997, 40, 1381-1390 and previous papers in the series.
9. (a) Wilson, W. R.; Tercel, M.; Anderson, R. F.; Denny, W. A. Radiation-activated prodrugs as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts. Anti-Cancer Drug Des. 1998, 13, 663-685.
10. (b) Naylor, M. A.; Stephens, M. A.; Stratford, I. J.; Keohane, A.; O'Neill, P.; Threadgill, M. D.; Webb, P.; Fielden, E. M.; Adams, G. E. Aziridinyl nitropyrroles and nitropyrazoles as hypoxia-selective cytotoxins and radiosensitizers. Anti-Cancer Drug Des. 1991, 6, 151-167.
11. (c) Denny, W. A.; Wilson, W. R. Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells. J. Med. Chem. 1986, 29, 879-887.
12. (a) Denny, W. A. Wilson, W. R. Bioreducible mustards: A paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer Metastasis Rev. 1993, 12, 135-151.
13. (b) Lee, H. H.; Palmer B. D.; Wilson, W. R.; Denny, W. A. Synthesis and hypoxia-selective cytotoxicity of a 2-nitroimidazole mustard. Bioorg. Med. Chem. Lett. 1998, 8, 1741-1744.
14. (c) Tercel, M.; Wilson, W. R.; Anderson, R. F.; Denny, W. A. Hypoxia-selective antitumor agents. 12. Nitrobenzyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine. J. Med. Chem. 1996, 39, 1084-1094.
15. (a) Borch, R. F.; Valente, R. R. Synthesis, activation, and cytotoxicity of aldophosphamide analogues. J. Med. Chem. 1991, 34, 3052-3058.
16. (b) Firestone, A.; Mulcahy. R. T.; Borch, R. F. Nitroheterocycle reduction as a paradigm for intramolecular catalysis of drug delivery to hypoxic cells. J. Med. Chem. 1991, 34, 2933-2935.
17. (c) Mulcahy, R. T.; Gipp, J. J.; Schmidt, J. P.; Joswig, C.; Borch, R. F. Nitrobenzyl phosphorodiamidates as potential hypoxia-selective alkylating agents. J. Med. Chem. 1994, 37, 1610-1615.
18. (d) Morgan, A. S.; Sanderson, P. E.; Borch, R. F.; Tew, K. D.; Niitsu, Y.; Takayama, T.; Von Hoff, D. D.; Izbicka, E.; Mangold, G.; Paul, C.; Broberg, U.; Mannervik, B.; Henner, W. D.; Kauvar, L. M. Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase. Cancer Res. 1998, 58, 2568-2575.
19. Patrick, T. M.; Emerson, W. S. 5-Nitro-2-thiophenealdehyde. J. Am. Chem. Soc: 1952, 74, 1356-1357.
20. Ronsisvalle, G.; Pappalardo, M. S.; Vittorio, F.; Pasquinucci, L.; Caruso, A.; Felice, A.; Amico-Roxas, M. Synthesis and pharmaceutical properties of N-thienyl alkylenediamines. Eur J. Med. Chem. 1988, 23, 553-559.
21. Janda, M.; Valenta, M.; Holy, P. Radical bromination of methyl 2,5-dimethyl-3-thiophenecarboxylate. Collect. Czech. Chem. Commun. 1974, 39, 959-962.
22. Bellenghi, M.; Carrara, G.; Fava, F.; Ginoulhiac, E.; Martinuzzi, C.; Vecchi, A.; Weitnauer, G. Sintesie attività antibiotica di nitroderivati del tiofene. Nitroderivati di 2-tiofenchetoni, 2-tienilalchil-carbinoli, 1-(2′-tienil)-alchilamine, di 2-tenoilamidi, della tiofenina e del 2-jodotiofene. Gazz. Chim. Ital. 1952, 82, 773-801.
23. 13C NMR Spectra of 1-methyl-nitropyrrole-2-aldehydes and related compounds. Chem. Scrip. 1980, 16, 72-76.
24. Rufer, C.; Schwarz, K.; Winterfeldt, E. Darstellung von 5-nitroimidazolen mit heterocyclen in 2-position. Liebigs Ann. Chem. 1975, 1465-1477.
25. Shulman-Roskes, E. M.; Noe, D. A.; Gamcsik, M. P.; Marlow, A. L.; Hilton, J.; Hausheer, F. H.; Colvin, O. M.; Ludeman, S. M. The partitioning of phosphoramide mustard and its aziridinium ions among alkylation and P-N bond hydrolysis reactions. J. Med. Chem. 1998, 41, 515-529.